Immune-based treatments represent a new group of therapeutic strategies for patients with cancer, including chronic lymphocytic leukemia (CLL), that employ immune effector mechanisms. Among these strategies is passive immunotherapy with monoclonal antibody, alone or in combination with chemotherapy. Active immunotherapy strategies currently under development include vaccines, administration of expanded and activated T cells, and allogeneic stem cell transplantation. These immune-based strategies represent new treatments with potentially complementary mechanisms of action to standard therapies and signify major advances in treatments for patients with CLL.
INTRODUCTION
Immune-based treatment strategies offer exciting new treatment options for patients with chronic lymphocytic leukemia (CLL). Certainly, harnessing and utilizing the immune system's great potential as a therapeutic modality against malignancy offers a unique and powerful spectrum of tools distinct from traditional chemotherapy.
Passive immune therapy involves transfer of antigen-specific antibodies to an individual and is effective in patients with CLL (Table 1) . Molecular biology has enabled production of large amounts of monoclonal antibody (mAb) directed against surface antigens found on CLL B cells. Such mAbs can be used alone or in combination with chemotherapeutic agents in the treatment of patients with CLL. Already, mAbs such as alemtuzumab and rituximab have significantly advanced the treatment of CLL.
Active immune therapy invokes adaptive immunity and is induced by exposure to antigen, thereby inducing specific lymphocyte responses (Table 1) . Specifically, vaccine strategies are being developed that induce or enhance T-cell responses against autologous leukemia cells. This review will discuss these immunologic treatment strategies and review outcomes of clinical trials using immune-based treatment strategies in patients with CLL.
mAb THERAPY
The binding of an mAb to its respective antigen on the surface of the CLL B cells can target the neoplastic cell for destruction through a variety of mechanisms. One such mechanism is antibody-dependent cellular cytotoxicity. In addition, leukemia cells coated with bound mAb may be targeted for clearance by the reticuloendothelial system. Another mechanism may be through compliment activation leading to lysis of the antibody-bound target cell. Finally, the binding of mAb to certain surface proteins on leukemia cells may directly kill leukemia cells by activating an apoptotic cascade or by blocking the binding of signaling factors responsible for maintaining leukemia-cell viability, both independent of extrinsic effector mechanisms.
CLL B cells as well as normal B and T cells. 1 Alemtuzumab was approved by the US Food and Drug Administration as a single agent for patients with fludarabine-refractory CLL. In the pivotal trial, alemtuzumab was administered to fludarabine-refractory patients at a standard dose of 30 mg intravenous (IV) three times weekly for a total of 12 weeks (Table 2) . 2 The overall objective response in 93 patients was 33%, with 2% complete remission (CR) and 31% partial remission (PR). The median time to progression for responders was 9.5 months; clinical benefit was noted in both responders and those with stable disease. The overall median survival was 16 months, 32 months for responders. Notable infections occurred in a little more than a quarter of the patients. Overall, treatment with alemtuzumab provided benefit for patients with very poor prognosis. Subsequent studies confirmed the activity of alemtuzumab in previously treated patients with CLL and when administered via subcutaneous (SQ) administration.
3-7 Higher response rates were observed in chemotherapy-naïve patients who receive alemtuzumab as front-line therapy. 8 Alemtuzumab 30 mg SQ three times weekly for up to 18 weeks produced 19% CR and 68% PR in 38 previously untreated patients with CLL. A number of these studies found that alemtuzumab was highly effective in clearing leukemia cells from the blood and marrow, but less active in clearing bulky lymph nodes. Also, alemtuzumab may be effective in clearing leukemia cells that lack p53 function. 9,10 Such leukemia 
Rituximab
Rituximab (anti-CD20 mAb) is a humanized mAb that binds to human CD20. 12 Relatively low levels of CD20 typically are expressed on CLL B cells compared with that expressed by normal or neoplastic B cells of other lymphomas. 13 Also, the plasma of patients with CLL may contain soluble CD20 that can inhibit the capacity of rituximab to bind to CLL B cells in vivo.
14 This likely influences the pharmacokinetics and clinical activity of rituximab in patients with CLL. At the standard dose of 375 mg/m 2 weekly for 4 weeks, single-agent rituximab had only modest anti-leukemia cell activity in CLL ( Table  2) . [15] [16] [17] [18] Rituximab also has been evaluated as a single agent in previously untreated patients with CLL, using 375 mg/m 2 of rituximab weekly for 4 weeks with subsequent maintenance therapy consisting of the same at six-month intervals for a total of two years. 21, 22 There were a total of 44 small lymphocytic lymphoma/CLL chemotherapy-naïve patients enrolled on this trial. Following the first course of rituximab, the complete and overall response rates were 4% and 51%, and 49% had stable disease after therapy. The complete and overall response rates upon completion of therapy were 9% and 58%, respectively. The estimated median progression-free time was 19 months. Overall, single-agent rituximab was well tolerated, however, much higher response rates have been seen when rituximab is combined with chemotherapy. Finally, unlike the responses to rituximab in other B cell malignancies (eg, follicular lymphoma), the response to rituximab for patients with CLL does not appear to be affected by Fc receptor polymorphisms. 23 
Combined Alemtuzumab and Rituximab
The combination of alemtuzumab and rituximab has been evaluated in patients with relapsed and refractory lymphoid malignancies. 24 Alemtuzumab was administered in a ramp-up dose to 30 mg IV during the first week and then twice weekly at 30 mg IV for the subsequent 3 weeks.
Rituximab was administered concurrently at 375 mg/m 2 weekly for all 4 weeks. Responses were reported for 48 patients: 32 with CLL, nine with CLL/prolymphocytic leukemia (PLL), one with PLL, four with mantle-cell lymphoma, and two with Richter's transformation. The overall response rate was 52%; CR was noted in 8%, nodular PR (nPR) in 4%, and PR in 40% of treated patients. The median time to progression and overall survival were 6 and 11 months, respectively. Toxicities included infusionrelated reactions. Infections occurred in 52% of patients with cytomegalovirus reactivation occurring in 27% of patients. Overall, this was a well-tolerated combination for relapsed patients with CLL.
Lumiliximab
Lumiliximab (anti-CD23 mAb) is a macaque-human chimeric antihuman CD23 mAb that has been evaluated in a phase I clinical trial for previously treated patients with CLL. 25 Increasing doses of lumiliximab up to 500 mg/m 2 three times weekly for 4 weeks were studied. No doselimiting toxicities were identified, and decreases in absolute lymphocyte counts were noted in more than 90% of the patients; reduction of 50% or more occurred in more than one fourth of patients. Reduction in lymph node size occurred in 59%. However, there were no complete or partial responders by National Cancer Institute criteria in this phase I trial. Lumiliximab is currently being evaluated in combination chemoimmunotherapy regimens.
Apolizumab
The mAb apolizumab (HU1D10; anti-MHC II) binds an epitope found on the alpha-chain of HLA-DR. 26 This epitope is found on HLA-DR expressed on B cells and monocytes of healthy donors as well as on the leukemia B cells of many patents with CLL. Apolizumab can directly induce apoptosis in primary lymphoma and CLL B cells. 26 A phase I clinical trial with increasing doses of apolizumab for four weekly infusions was conducted in patients with lymphoma. 27 Subsequently, a phase I study of thriceweekly apolizumab was conducted in patients with relapsed or refractory CLL. 28 At last report, it appeared that the maximum-tolerated dose of apolizumab was 3 mg/kg IV three times weekly for 4 weeks. Pharmacodynamic studies demonstrated phosphorylation of the protein akt in CLL B cells of apolizumab-treated patients. 29 Such studies suggest that apolizumab may induce both death and survival signals in CLL B cells.
Anti-CD40 mAb
CD40 is a B-cell surface molecule that is ubiquitously expressed in CLL. CD40 has functional significance in CLL whereby ligation may provide survival and proliferation signals to the leukemic B cells. 30, 31 A fully humanized anti-CD40 mAb (CHIR-12.12) has been produced that Immunotherapies for CLL www.jco.orghas blocking activity. 32, 33 In vitro, this mAb blocks CD154-mediated stimulation of primary leukemia B cells. Culture of CLL B cells with anti-CD40 mAb induced apoptosis in primary CLL B cells as well as facilitated ADCC against CD40 ϩ targets. 32 These in vitro studies form the rationale for conducting a phase I clinical trial of anti-CD40 mAb in previously treated patients with CLL.
CHEMOIMMUNOTHERAPY
Cytotoxic chemotherapy and mAb have synergistic activity in patients with CLL. In vitro, fludarabine downmodulates expression of complement-resistance proteins CD49, CD55 and CD59, possibly making the treated cells more susceptible to rituximab-induced compliment-mediated lysis. 34 Conversely, rituximab downmodulates expression of bcl-2, making leukemia cells more susceptible to fludarabine-induced apoptosis.
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Fludarabine and Rituximab
Combinations of rituximab with purine analoguebased therapy have been evaluated (Table 3 ). In CALGB (Cancer and Leukemia Group B) 9712, 36 previously untreated patients received six courses of either sequential or concurrent fludarabine and rituximab followed 2 months later with an additional 4 weeks of single-agent rituximab for responders or patients with stable disease. Fludarabine was administered at the standard dose of 25 mg/m 2 daily for 5 days of each 4-week course; for those patients receiving concurrent therapy, rituximab was also administered at 375 mg/m 2 day 1 with each course. This randomized clinical trial of 104 patients demonstrated statistically significantly higher CR with concurrent versus sequential therapy. However, patients treated in the group that received concurrent therapy were administered 2.5 times the amount of rituximab, compromising headto-head comparisons between these two groups. Nevertheless, survival advantage has not been demonstrated for either group. In a historical comparison of single-agent fludarabine (CALGB 9011), it appeared that previously untreated patients who receive rituximab as part of their initial therapy may have improved survival over those receiving single-agent fludarabine.
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Fludarabine and Alemtuzumab
Potential synergy between fludarabine and alemtuzumab was first suggested by a small trial of six patients who were treated with the combination after being refractory to fludarabine and alemtuzumab when used separately (Table 3). 38 One patient achieved CR by National Cancer Institute criteria, and four patients achieved PR. The FluCam regimen consists of fludarabine 30 mg/m 2 immediately followed by alemtuzumab 30 mg IV, both on days 1 through 3 of each 4-week course for a total of six courses. 39 This regimen has been evaluated in previously treated patients with reported CR and PR rates of 29% and 56%, respectively. Elimination of residual disease from blood was achieved in 44%. Therefore, FluCam is a promising regimen for previously treated patients with CLL.
Fludarabine, Cyclophosphamide, and Rituximab
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has been evaluated in both chemotherapy-naïve as well as previously treated patients with CLL (Table 3) . 40, 41 In this regimen, fludarabine and cyclophosphamide were administered at 25 mg/m 2 and 250 mg/m 2 , respectively, both days 1 through 3; rituximab was administered 375 mg/m 2 day 1, course 1, and 500 mg/m 2 day 1, courses 2 through 6. Treatment was every 4 weeks for a total of six courses. In previously untreated patients, the CR rate with this regimen was 70% and overall response rate was 95%, with most patients having no detectable disease by flow cytometry evaluation of the bone marrow at the end of therapy. 40 The projected failure-free survival at 4 years was 69%. This was the highest response rate reported for any regimen in previously untreated patients.
Relapsed and refractory patients also were treated with FCR. For 177 previously treated patients with a median of two prior therapies, 25% achieved CR and the overall response rate was 75%. Approximately one third of the complete responders tested had no detectable disease in the bone marrow by polymerase chain reaction evaluation. The estimated median survival for all 177 patients was 42 months. Therefore, this regimen also has significant activity in previously treated patients with CLL.
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Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab
Alemtuzumab was combined with FCR (CFAR) for previously treated patients with CLL (Table 3) . 42 In this regimen, alemtuzumab 30 mg IV on days 1, 3, and 5 of each course was added to FCR as administered in previous studies for a total of six courses. An early evaluation of 31 heavily pretreated patients who had a median of four prior treatments reported CR in 23% and an overall response rate of 55%. Nearly half of these patients were fludarabinerefractory and nearly half had previously received FCR as salvage therapy. This was a much more heavily pretreated patient group than that treated with FCR in the previously described study, making it difficult to compare complete and overall response rates. Despite the increase in the incidence of myleosuppression and thrombocytopenia in patients treated with CFAR, they did not experienced a significant increase in major infections over that of patients treated with FCR. Owing to the addition of alemtuzumab, there was an increase in cytomegalovirus reactivation with CFAR. CRs were good quality with elimination of minimal residual disease from marrow demonstrated by two-color flow cytometry.
Pentostatin, Cyclophosphamide, and Rituximab
Rituximab has been combined with pentostatin and cyclophosphamide (PCR) for chemotherapy-naïve and previously treated patients with CLL (Table 3) . 43, 44 In a trial for previously treated patients, cyclophosphamide was administered at 600 mg/m 2 on day 1, pentostatin 4 mg/m 2 on day 1, and rituximab at 375 mg/m 2 with each course beginning for course 2. 44 Courses were administered every 3 weeks, and all patients received granulocyte colonystimulating factor (G-CSF) support. At last report, 28 previously treated patients with CLL received this regimen and were assessable for response. In this subgroup, 79% responded with CR in 29%. This regimen was well tolerated, with the principle toxicity being myleosuppression. A similar regimen with a lower dose of pentostatin (2 mg/m 2 day 1), also with G-CSF support, was used to treat chemotherapy-naïve patients with CLL. A recent report of 33 previously untreated patients that received this regimen indicated that 33% achieved CR, 21% nPR, and 39% PR, for an overall response rate of 97%. 43 This regimen was well tolerated with nausea and vomiting as the most common nonhematologic toxicity. Accrual continues to both of these clinical trials.
Alemtuzumab for Residual Disease
For patients who have residual disease after purine analogue-based therapy, the marrow has been the major site of involvement. Elimination of residual disease, particularly in marrow, may enhance treatment outcome. Because of the significant activity of alemtuzumab at clearing blood and marrow of disease, there have been several studies to evaluate its ability to eliminate residual disease following chemotherapy.
47-51 One study evaluated a 4-to 8-week course of thrice-weekly alemtuzumab at a dose of 30 mg IV for recently treated patients who had achieved PR or had residual marrow disease documented either morphologically or by flow cytometry. 47 The overall response (downstaging) in this trial was 46% and residual marrow disease was cleared in most patients. Lack of response was due most commonly to residual adenopathy. Molecular remission was achieved in some patients after treatment with alemtuzumab.
In a study by the German CLL Study Group, patients who had recently received fludarabine or fludarabine with cyclophosphamide were randomly assigned to observation versus consolidation with alemtuzumab. 50 This trial was terminated early due to significant infection-related toxicity in the patients who received alemtuzumab. However, alemtuzumab was highly effective at eliminating minimal residual disease with sustained responses and significantly improved disease-related clinical outcome. 52 Therefore, studies to identify optimal dose and schedule of alemtuzumab consolidation continue.
Alemtuzumab has also been evaluated as maintenance therapy. 53 Alemtuzumab 30 mg IV three times weekly was administered for 9 to 12 weeks followed by monthly maintenance dose of 30 mg IV for at least 4 months. Compared to an historic group that received standard dose alemtuzumab followed by observation, the 11 heavily pretreated patients that received maintenance therapy had longer progression-free and overall survival.
CELLULAR THERAPY
The T cells of patients with CLL display phenotypic and functional defects that are brought about by the presence of leukemic B cells. These defects result in dysregulation of T-cell immunity and overall immunosuppression. Current treatments for CLL, including purine analogues, exacerbate immune deficiency by depleting already dysfunctional T cells, thereby reducing protection from infection. A process has been developed in which T cells can be activated and expanded ex vivo up to 100-to 1,000-fold via a process referred to as the Xcellerate process. 54 With this process, T cells are obtained by leukapheresis and cultured with magnetic beads coated with mAbs against CD3 and CD28 in the presence of interleukin-2. During expansion, T cells also may regain their capacity to respond to antigen.
A phase I/II dose-escalation clinical trial with Xcellerated T cells for patients with CLL was recently reported. 54 Doses up to 100 ϫ 10 9 autologous Xcellerated T cells were administered as a single infusion to patients with CLL. Xcellerated T cells were well tolerated with no doselimiting toxicities reported. The treatment resulted in consistent dose-dependent increases in blood T-cell counts and reduction in the lymph nodes and spleen. In addition, there were improvements in absolute neutrophil counts, hemoglobin, and platelet counts, suggesting overall clinical improvement. Disappointingly, reductions in blood leukemia cell counts were not observed. A phase II clinical trial is planned with Xcellerated T cells following debulking therapy in previously treated patients with CLL.
VACCINE STRATEGIES FOR TREATMENT OF CLL
Vaccine strategies have been under investigation for many years for treatment of various malignancies. The rationale behind vaccine strategies is to induce host cell-mediated immune responses against autologous malignant cells as the modality to eliminate tumor and to provide lasting protection from recurrence. Various vaccine strategies have been studied for patients with CLL, including vaccination with modified autologous leukemic cells and use of antigen-pulsed dendritic cells.
One vaccination strategy utilized modified autologous leukemic cells. 55 A replication-defective adenovirus vector was employed to transduce CLL B cells to express the gene encoding CD154 (CD40 ligand). Upon expression of CD154, CD40 was cross linked on transduced cells as well as bystander cells, thereby inducing them to express co-stimulatory antigens, such as CD80 and CD86. This phenotypic transformation imparts the ability of these cells to present antigen to autologous T cells. The end result was to stimulate an effective T-cell immune response against autologous leukemia cells. A phase I clinical trial was performed employing this strategy for patients with CLL. There were no dose-limiting toxicities noted and there were significant clinical responses noted in several patients, including reductions in leukemic cell counts and in the size of lymph nodes and spleen. Also, treatment increased numbers of blood T cells, including T cells specific for autologous leukemic cells.
Cross linking CD40 on CLL B cells also induced physiologic changes in the leukemia cells that made them more susceptible to apoptosis.
56 Expression or upregulation of CD95, the receptor for Fas (CD178), occurred with CD40 ligation. Also, CLL B cells expressed bid, a proapoptotic protein that facilitates cross talk between mitochondria-dependent apoptosis and death receptors such as DR5. Increased expression of bid may make cells more susceptible to chemotherapy-induced apoptosis. DR5, a death-receptor for TNF (tumor necrosis factor) -Related Apoptosis Inducing Ligand (TRAIL) also was expressed on CLL B cells after CD40 ligation. Before CD40 activation, CLL B cells were unaffected by ligation of CD95 or DR5. However, following ligation of CD40 the leukemia cells became sensitive to apoptosis induced by ligation of CD95 and/or DR5. Greater levels of killing were seen when both death-receptors were ligated simultaneously. Activated T cells express both Fas ligand (CD178) and TRAIL, and may function to kill CLL B cells through this mechanism. This provides a potential second mechanism of action in addition to T cellmediated immunity.
A similar strategy of vaccination employed SQ administration of autologous CLL B cells modified to express CD154 and IL-2.
57 In a report, eight patients received treatment with autologous modified leukemia cells on this phase I clinical trial. Several of these patients developed enhanced T-cell reactivity against autologous CLL B cells.
In another study, early-stage patients were vaccinated with oxidized autologous leukemia cells. 58 Clinical responses were noted in five of 18 patients that were associated with enhanced T-cell antitumor activity. Six patients had stable disease, and six of the 18 patients had progression. No significant toxicities were associated with this treatment.
Dendritic cells are highly effective antigen-presenting cells. They can be primed to take up antigen and then present it to T cells, resulting in T-cell activation and proliferation in response to the presented antigen. Dendritic cell fusions with autologous tumor cells have been evaluated as a vaccine strategy for patients with malignancy. Such dendritic cell-based vaccine strategies are currently in development for clinical trial; however, to date there are no trial results available in CLL.
59-61
CONCLUSION
Immune-based strategies can utilize passive or active effector modalities including mAbs, cellular therapies, and vaccines. mAbs have therapeutic activity alone and in combination with chemotherapy and have been incorporated into standard treatments for patients with CLL. Vaccines and cellular therapies are under investigation in clinical trials and have clinical activity. Work continues toward developing new treatments with immune-based mechanisms for patients with CLL.
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